X-Linked Retinitis Pigmentosa Clinical Trial
Official title:
A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa
Verified date | March 2024 |
Source | Beacon Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
Status | Enrolling by invitation |
Enrollment | 18 |
Est. completion date | August 2029 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Be at least 12 years of age - Have one eye previously treated with an AAV vector-based gene therapy designed to provide full-length functioning RPGR protein. - Have a BCVA no better than 78 letters and no worse than 34 letters - Be able to perform all tests of visual and retinal function and structure in both eyes based on the participant's reliability and fixation, per the Investigator's discretion. - Have detectable baseline mean macular sensitivity measured by MAIA microperimetry, as determined by the Investigator and confirmed by the Central Reading Center (CRC). - Have detectable EZ line in the study eye as assessed by SD-OCT and confirmed by the CRC. Exclusion Criteria: - Have other known disease-causing mutations documented in the participant's medical history or identified through a retinal dystrophy gene panel that, in the opinion of the Investigator, would interfere with the potential therapeutic effect of the study agent or the quality of the assessments. - Have pre-existing eye conditions that would preclude the planned surgery, interfere with the interpretation of study endpoints, or increase the risk of surgical complications - Had intraocular surgery within 90 days of study treatment administration. - Have any active ocular/intraocular infection or inflammation - Have a history of steroid-induced raised IOP of >25 mmHg following corticosteroid exposure, despite topical IOP-lowering pharmacologic therapy. |
Country | Name | City | State |
---|---|---|---|
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Cincinnati Eye Institute | Cincinnati | Ohio |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Retina Foundation of the Southwest | Dallas | Texas |
United States | University of Florida | Jacksonville | Florida |
United States | Bascom Palmer Eye Institute | Miami | Florida |
United States | Casey Eye Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Beacon Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary safety outcome is the number and proportion of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs). | Day 0 - Month 12 | ||
Secondary | Change from baseline in mean sensitivity across the whole grid, as measured by MAIA microperimetry | Day 0 - Month 12 | ||
Secondary | Response, as measured by MAIA microperimetry, where response is defined as a greater than or equal to 7 dB visual sensitivity improvement from baseline in at least 7 loci. | Day 0 - Month 12 | ||
Secondary | Change from baseline in BCVA using Early-Treatment Diabetic Retinopathy Study (ETDRS) visual acuity | Day 0 - Month 12 | ||
Secondary | Change from baseline in LLVA using ETDRS visual acuity | Day 0 - Month 12 | ||
Secondary | Change from baseline in Ora-VNC mobility test score | Day 0 - Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04926129 -
Natural History of the Progression of X-Linked Retinitis Pigmentosa
|
||
Recruiting |
NCT05926583 -
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
|
Phase 3 | |
Completed |
NCT03116113 -
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
|
Phase 1/Phase 2 | |
Recruiting |
NCT04850118 -
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04517149 -
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT03584165 -
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
|
Phase 3 | |
Active, not recruiting |
NCT04312672 -
Long-term Follow-up Gene Therapy Study for RPGR- XLRP
|
||
Completed |
NCT04868916 -
An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa
|
||
Completed |
NCT03252847 -
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05874310 -
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
|
Early Phase 1 | |
Active, not recruiting |
NCT04794101 -
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
|
Phase 3 | |
Active, not recruiting |
NCT04671433 -
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
|
Phase 3 | |
Completed |
NCT03314207 -
Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)
|
||
Active, not recruiting |
NCT03316560 -
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06333249 -
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
|
Phase 2 |